These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation. Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M; Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951 [TBL] [Abstract][Full Text] [Related]
12. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy. Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803 [TBL] [Abstract][Full Text] [Related]
14. ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Nordén G; Briggs D; Cockwell P; Lipkin G; Mjörnstedt L; Mölne J; Ready A; Rydberg L; Samuelsson O; Svalander CT; Breimer ME Xenotransplantation; 2006 Mar; 13(2):148-53. PubMed ID: 16623810 [TBL] [Abstract][Full Text] [Related]
15. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Sawada T; Fuchinoue S; Teraoka S Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255 [TBL] [Abstract][Full Text] [Related]
16. ABO-incompatible kidney transplantation. Schousboe K; Titlestad K; Baudier F; Hansen LU; Bistrup C Dan Med Bull; 2010 Oct; 57(10):A4197. PubMed ID: 21040684 [TBL] [Abstract][Full Text] [Related]
17. Association between response to rituximab and antibody-mediated rejection in ABO-incompatible living kidney transplantation. Maenosono R; Unagami K; Kakuta Y; Furusawa M; Okumi M; Azuma H; Ishida H; Tanabe K Int J Urol; 2019 Dec; 26(12):1114-1120. PubMed ID: 31522467 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622 [TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. Serinet MO; Jacquemin E; Habes D; Debray D; Fabre M; Bernard O J Pediatr Gastroenterol Nutr; 2002 Apr; 34(4):389-93. PubMed ID: 11930095 [TBL] [Abstract][Full Text] [Related]
20. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]